Carbapenems: Definition, Mechanism, Types, and Uses
Carbapenems represent a critical and highly potent subclass of the beta-lactam family of antibiotics. They are distinguished by a broad spectrum of activity against many types of bacteria, including those resistant to most other antimicrobial agents. Consequently, they are typically reserved as “last-line agents” or “antibiotics of last resort” for treating severe, known or suspected multidrug-resistant (MDR) bacterial infections, which often include serious hospital-acquired infections. The World Health Organization (WHO) lists a prominent carbapenem, meropenem, as an essential medicine. Their structure includes a characteristic beta-lactam ring fused to a five-membered ring where the sulfur at C-1 is replaced by a carbon atom, which gives them the “carbapenem” designation. This unique chemical architecture, particularly the *trans* configuration and C-6 hydroxyethyl side chain, contributes significantly to their exceptional stability against most bacterial beta-lactamase enzymes, which destroy many other beta-lactam drugs.
Mechanism of Action
Like all other beta-lactam antibiotics, carbapenems are bactericidal agents that primarily target the bacterial cell wall. Their mechanism involves inhibiting the final, essential stage of bacterial cell wall synthesis. The core of their power lies in their high-affinity binding to and inactivation of crucial bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are also referred to as DD-transpeptidases. PBPs are physiologically responsible for the cross-linking of peptidoglycan chains, a process fundamental for the structural integrity and rigidity of the bacterial cell wall. By binding to and deactivating these proteins, carbapenems effectively prevent the cross-linking step, leading to the formation of a defective, weakened cell wall. This compromised structure cannot withstand the internal osmotic pressure of the bacterium, resulting in the lysis and eventual death of the bacterial cell. This mechanism provides them with powerful bactericidal properties against both Gram-positive and Gram-negative bacteria.
Types, Structure, and Chemical Features
The first reported carbapenem, Thienamycin, was isolated from *Streptomyces cattleya* in 1976 and served as the parent compound and structural model for all subsequent clinically approved carbapenems. The common carbapenems approved for global clinical use include Imipenem, Meropenem, Ertapenem, and Doripenem, while others like Tebipenem and Biapenem are approved in specific regions like Japan. A key structural feature across the class is the *trans* configuration of the C5-C6 bond and the C-6 (*R*)-hydroxyethyl substituent; this provides better resistance against bacterial beta-lactamases.
Imipenem, the first to be clinically used (approved in the USA in 1985), is unique because it is hydrolyzed in the mammalian kidney by the enzyme dehydropeptidase-1 (DHP-1). This rapid degradation creates a nephrotoxic intermediate and limits the antibiotic’s half-life. Therefore, Imipenem is always co-administered with cilastatin, a specific DHP-1 inhibitor, which protects the Imipenem from breakdown and prolongs its therapeutic effect. Meropenem was chemically engineered to include a methyl group at the 1$beta$ position, which intrinsically increases its stability against DHP-1, thereby eliminating the need for co-administration with cilastatin. This structural difference makes meropenem a safer and preferred option for central nervous system (CNS) infections like meningitis due to its significantly lower risk of inducing seizures compared to imipenem. Ertapenem is characterized by its long half-life, allowing for once-daily dosing, but it is known to possess a narrower spectrum, notably lacking significant activity against *Pseudomonas aeruginosa*, *Acinetobacter* species, and most *Enterococcus* species. Newer drug combinations, such as Meropenem/vaborbactam and Imipenem/cilastatin/relebactam, include novel beta-lactamase inhibitors to specifically combat certain emerging resistance mechanisms.
Uses and Spectrum of Activity
Carbapenems are characterized by an extremely broad spectrum of activity, which is one of the broadest among all available antibiotics. They are generally effective against a wide range of clinically significant pathogens, including most Gram-negative rods (e.g., *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, and *Pseudomonas aeruginosa*, though Ertapenem is inactive against the last two), most Gram-positive cocci (e.g., most *Streptococcus* species and methicillin-sensitive *Staphylococcus* species), and most anaerobic bacteria (e.g., *Bacteroides fragilis*). However, they are not highly active against methicillin-resistant *Staphylococcus aureus* (MRSA) or most *Enterococcus faecium* infections because they do not effectively bind to the specific penicillin-binding proteins used by these resistant pathogens. Given this broad coverage, their medical uses are strictly reserved for severe, complex, and multidrug-resistant infections, including complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), late-onset hospital-acquired and ventilator-associated pneumonia, sepsis, bloodstream infections, and bacterial meningitis (for which Meropenem is the first-line choice).
Carbapenem Resistance and Safety Profile
The widespread use of carbapenems has led to a major global public health problem: the emergence of carbapenem resistance. The main driver of this resistance is the enzymatic destruction of the antibiotic by bacterial enzymes called **carbapenemases**, which are a type of $beta$-lactamase. These enzymes are classified into major groups: Class A (e.g., *Klebsiella pneumoniae* carbapenemase or KPC) and Class D (OXA-type $beta$-lactamases) are serine $beta$-lactamases, while Class B are Metallo-Beta-Lactamases (MBLs), which use zinc to mediate hydrolysis (e.g., NDM-1). MBLs are particularly concerning because they are not inhibited by the $beta$-lactamase inhibitors currently co-formulated with carbapenems. Other important resistance mechanisms include decreased drug permeability due to the loss or alteration of outer cell membrane porin channels, and the expression of efflux pumps that actively transport the antibiotic out of the bacterial cell. To counter the rising resistance, novel $beta$-lactamase inhibitors like vaborbactam (with meropenem) and relebactam (with imipenem/cilastatin) have been developed to restore activity against serine carbapenemase-producing pathogens.
In terms of safety, carbapenems are generally well-tolerated. The most common adverse reactions are gastrointestinal symptoms such as diarrhea, nausea, and vomiting. A major side effect, particularly associated with Imipenem, is the risk of neurological adverse events, most notably seizures. This risk is dose-related and significantly higher in patients with pre-existing CNS abnormalities or renal impairment. Due to the structural similarity to penicillins, there is a small chance of cross-hypersensitivity, meaning patients with a penicillin allergy may rarely experience an allergic reaction to a carbapenem. Carbapenems are excreted in breast milk at low concentrations, and their use during pregnancy is typically restricted to situations where no safer, effective antibiotic alternative is available.